| Dec 10, 2010
| 11:29 AM
NEW YORK -- Johnson & Johnson on Thursday recalled several types of Rolaids antacids in the U.S. because of reports of metal and wood particles in the products.
The voluntary recall comes less than a month after the company issued another voluntary...
| Aug 10, 2011
| 10:55 AM
LOS ANGELES (Reuters) - U.S. regulators are moving quickly with Roche's application for targeted melanoma drug vemurafenib, which could receive approval as early as this week, according to a source familiar with the situation.
A pivotal trial found...
| Aug 28, 2011
| 7:37 AM
PARIS (Reuters) - An experimental anti-clotting drug from Bristol-Myers Squibb and Pfizer saved more lives than standard treatment warfarin in a major study, giving it an edge over rivals in an emerging multibillion-dollar market.
Although Eliquis will...
| Sep 7, 2011
| 9:21 AM
LONDON (Reuters) - Johnson & Johnson's prostate cancer drug Zytiga has been approved in the European Union, paving the way for the launch of a new treatment for men whose disease has progressed after chemotherapy, the company said on Wednesday.
| Mar 30, 2011
| 2:07 AM
More bottles of Tylenol being recalled this morning because of problems at a Pennsylvania plant.
Johnson and Johnson recalling bottles of Tylenol 8-hour caplets after complaints of a musty or mold odor.
Taking the pills that have an odor could lead to...
| Sep 26, 2011
| 8:30 PM
(Reuters) - Johnson & Johnson has told doctors it expects a limited supply of its Doxil cancer drug to become available within the next six weeks, but warned the amount would not be sufficient for all patients currently on waiting lists.
| Jan 3, 2011
A blood test that could spot a single cancer cell among a billion healthy ones is moving one step closer to being available at your doctor's office, researchers announced Monday.
According to Johnson & Johnson, a $30-million investment in a new test that...
| Jan 8, 2011
Although first approved to treat schizophrenia, new antipsychotic medications are increasingly being prescribed for a host of other uses, even when there is little evidence they work, U.S. researchers said on Friday.
The drugs, known as "atypical...
| May 23, 2011
| 3:53 PM
Vertex Pharmaceuticals Inc's highly anticipated hepatitis C drug won U.S. approval, promising far higher cure rates for the liver-destroying disease and setting up a head-to-head marketing battle with a rival new medicine from Merck & Co.
Incivek, a pill...
| Jun 12, 2011
| 8:02 PM
NEW YORK (KTLA) -- The number of drug shortages is at a record high, and the Food and Drug Administration is warning that they are getting even worse.
Fueling the problem are shortages of raw materials. Also, drugmakers are discontinuing older, and off-...
| Jun 15, 2011
| 3:57 AM
CHICAGO (Reuters) - New labeling rules for sunscreens should make it easier for U.S. consumers to choose products that will protect them from sunburn, skin cancer and premature aging.
The U.S. Food and Drug Administration ruled on Tuesday that sunscreens...